StreetAlpha.app
Home › Stocks › ACTU

Actuate Therapeutics, Inc. (ACTU)

$0.26
▼ −7.72%
LAST CLOSE · NOV 17

Actuate Therapeutics develops elraglusib, an experimental cancer drug that targets the GSK-3β enzyme in tumors. It last closed at $0.26 on Nov 17, down 7.72% on the day.

AI Auto Pilots
Is ACTU in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$18.5M
EPS (diluted)
−$0.76
−323.5% vs a year ago
Valuation
Market cap
$15.6M
60.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.1M
At Sep 30
Debt
$405K
At Sep 30
Shareholder equity
−$809K
Shares outstanding
60.4M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$24.7M−$24.7MFY2023FY2024: −$27.3M−$27.3MFY2024FY2025: −$22.2M−$22.2MFY2025

From ACTU's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ACTU in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 3771.5% upside

Based on 1 analyst who set a price target on ACTU in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $0.26.

Low $10.00Avg $10.00High $10.00
Blue marker: last close $0.26
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 16Buy$15 → $10
HC Wainwright & Co.Reiterated
Aug 18Buy$15
Rodman & RenshawInitiated
Jul 30Buy$6
DateFirmActionRatingPrice target
Nov 16HC Wainwright & Co.Target loweredBuy$15 → $10
Aug 18HC Wainwright & Co.ReiteratedBuy$15
Jul 30Rodman & RenshawInitiatedBuy$6
Loading…

Technical Analysis

ACTU · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 42% below its 20 day and 140% below its 50 day average. It is 620% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $0.24, and the nearest resistance the Pivot at $0.26.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 27.9%/day
Key levels
$7.9052 week high+2938.5%
$1.86200 day average+615.4%
$0.97100 day average+273.1%
$0.6250 day average+138.5%
$0.3720 day average+42.3%
$0.35Swing high (Nov 12)+34.6%
$0.28Pivot R1+7.7%
$0.26Pivot+0.0%
$0.26Last close
$0.2452 week low−7.7%
$0.24Pivot S1−7.7%
Indicators
RSI (14)29.27Oversold below 30Oversold
MACD-0.10Above its signal lineBullish
Stochastic9.5Near the bottom of its rangeOversold
ADX (14)25.3Trending down
Williams %R-89.8Oversold below −80, overbought above −20Oversold
CCI (20)-107.8Oversold below −100, overbought above 100Oversold
Rate of change−23.5%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 27.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACTU

What happened before

See how ACTU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in ACTU in the last 90 days.

Loading…

See today’s whale options flow across the market →

ACTU Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼9 buying vs 42 selling
  • ●Held by funds -0.4 pts
  • ▼Funds holding -24
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4064−37.5%
In funds' top 10110.0%
Held by funds22.0%22.4%−0.4 pts
New / increased4 / 516 / 18−73.5%
Reduced / sold out15 / 2720 / 14+23.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACTU institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACTU is in one of them and how their past ACTU trades turned out.

ACTU in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACTU in an article yet. Here's the latest on the wider market.

About Actuate Therapeutics

Actuate Therapeutics is a biopharmaceutical company based in Fort Worth, Texas. It is developing elraglusib, an experimental cancer drug designed to block an enzyme that helps tumors survive and grow. The company is testing the drug mainly in pancreatic cancer, and it is also studying pediatric cancers and other tumor types. It is developing both an injectable form and an oral tablet for patients with difficult to treat cancers.

Headquarters
Fort Worth, TX